These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29673369)

  • 1. Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.
    Ghaddar A; Khandaqji S; Abbass Z
    Subst Abuse Treat Prev Policy; 2018 Apr; 13(1):14. PubMed ID: 29673369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
    Richert T; Johnson B
    Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon.
    Ghaddar A; Abbas Z; Haddad R
    Harm Reduct J; 2017 Dec; 14(1):78. PubMed ID: 29216892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
    Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
    Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of a contraception clinic into an opioid treatment setting to improve contraception knowledge, accessibility and uptake: a pilot study.
    Day CA; White B; Reid SE; Fowler M; Black KI
    Aust N Z J Public Health; 2020 Oct; 44(5):360-362. PubMed ID: 32865845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing opioid substitution in Lebanon: Inception and challenges.
    El-Khoury J; Abbas Z; Nakhle PE; Matar MT
    Int J Drug Policy; 2016 May; 31():178-83. PubMed ID: 27114000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.
    Chandler A; Whittaker A; Cunningham-Burley S; Williams N; McGorm K; Mathews G
    Int J Drug Policy; 2013 Nov; 24(6):e35-42. PubMed ID: 23688832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study between prison- and community-based treatment satisfaction for opioid use disorder in Lebanon.
    Khalaf D; Hayek M; Bakhos JJ; Abou-Mrad F
    Int J Prison Health; 2019 Jun; 15(2):138-152. PubMed ID: 31172852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
    Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
    Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
    Oliva EM; Harris AH; Trafton JA; Gordon AJ
    Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing youth-centred opioid agonist treatment: Findings from a retrospective chart review of youths' characteristics and patterns of opioid agonist treatment engagement in a novel integrated youth services program.
    McInerney K; Marchand K; Buckley J; Gao C; Kestler A; Mathias S; Argyle A; Barbic S
    Early Interv Psychiatry; 2023 Oct; 17(10):1028-1037. PubMed ID: 37259685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.